National and Kapodistrian University of Athens
Study of new molecules with potential therapeutic activity in immune system disorders
Abstract
dc:descriptionInflammation and cancer are closely interconnected pathological processes that arise from dysregulated immune signaling, oxidative stress, and aberrant activation of intracellular signaling pathways. While acute inflammation constitutes an essential component of host defense, its chronic persistence contributes to genomic instability, tissue damage, and the formation of a tumor-supportive microenvironment. Concurrently, developing tumors exploit inflammatory mechanisms to promote their growth, evade immune surveillance, and remodel the surrounding tissues. This reciprocal relationship highlights the need for therapeutic approaches capable of targeting both inflammatory and oncogenic processes. Natural products, particularly olive-derived polyphenols such as oleuropein (OP) and oleocanthal (OC), have attracted interest due to their reported antioxidative, anti-inflammatory, and anticancer properties. Despite encouraging results in preclinical models, their therapeutic application is limited by low bioavailability, rapid metabolic clearance, and moderate potency. The present doctoral thesis addresses these limitations through the rational design and preclinical evaluation of semi-synthetic analogs of olive-derived polyphenols, aiming to identify compounds with improved biological activity and mechanistic specificity. The primary objective of this thesis was to identify, characterize, and mechanistically evaluate novel semi-synthetic analogs of OP and OC with enhanced therapeutic potential in immune-mediated inflammatory conditions and cancer. This was pursued through three complementary axes. Firstly, a library of 22 newly synthesized analogs was screened to identify compounds with superior anti-inflammatory and/or anticancer activity compared to the parental molecules, with emphasis on potency, selectivity, and safety toward non-malignant cells. Secondly, lead compounds were evaluated in established in vivo models of acute inflammation and cancer to assess whether their in vitro activity is translated into measurable therapeutic effects. Thirdly, cellular-, immunological-, and kinome-based approaches were employed to investigate the various mechanisms underlying the activity of the most promising compounds.Initial screening identified two structurally distinct lead compounds with divergent but complementary biological profiles. GS50 emerged as the most effective anti-inflammatory analog, whereas GS32 displayed the most pronounced anticancer activity. These compounds were, therefore, selected for further investigation as representative candidates targeting inflammation and cancer, respectively. GS50 exhibited consistent anti-inflammatory and antioxidative activity across multiple in vitro macrophage models of both human and murine origin. Under inflammatory stimulation, GS50 reduced reactive oxygen species production and suppressed the secretion of key pro-inflammatory cytokines, while exerting minimal cytotoxic effects on non-activated immune cells. This pattern suggests that GS50 primarily modulates inflammatory signaling rather than inducing nonspecific cytotoxicity. The anti-inflammatory activity of GS50 was subsequently confirmed in vivo using two models of acute inflammation: imiquimod-induced skin inflammation and acetic acid-induced colitis. In both models, treatment of mice with GS50 resulted in reduced macroscopic inflammation, preservation of tissue architecture, and decreased immune cell infiltration. The magnitude of these effects differed between mouse strains, with a more pronounced response observed in C57BL/6J mice compared to BALB/c mice, indicating a strain-dependent component that likely reflects differences in immune polarization between the two mouse strains. Taken together, these findings indicate that GS50 effectively attenuates acute inflammatory responses by targeting central inflammatory and oxidative stress-related pathways shared across different tissues and inflammatory stimuli. In addition to suppressing pro-inflammatory signaling, its ability to reduce reactive oxygen species production suggests that modulation of oxidative stress contributes to its overall mechanism of action. This dual anti-inflammatory and antioxidative activity profile supports its further evaluation as a candidate therapeutic compound for inflammatory conditions. GS32 was identified as the most potent anticancer analog, exhibiting cytotoxicity at very low micromolar concentrations across several human and murine cancer cell lines. GS32 demonstrated selectivity toward malignant cells while sparing normal immune cells, suggesting a favorable therapeutic window. Mechanistic analyses showed that GS32 suppressed tumor cell proliferation and induced apoptosis in a concentration- and time-dependent manner. These effects were accompanied by S-phase cell cycle arrest, consistent with interference with DNA replication and the associated immune checkpoint control mechanism. Importantly, GS32 did not solely exert cytostatic effects but actively promoted programmed cell death, indicating engagement of intrinsic stress-response pathways. Kinome profiling revealed that GS32 treatment resulted in a coordinated modulation of multiple signaling pathways. These included suppression of several serine/threonine kinases and altered activity of key protein tyrosine kinases, leading to broader reprogramming of pathways involved in proliferation, survival, inflammation, and cell cycle regulation. Network analyses supported the interpretation that these changes reflect integrated signaling responses rather than isolated kinase effects. The anticancer activity of GS32 was further validated in syngeneic mouse models of melanoma and colon carcinoma, where GS32 treatment delayed tumor growth without evidence of systemic toxicity. In addition to its direct effects on tumor cells, GS32 altered the tumor microenvironment by increasing both immune cell infiltration and activation. Ex vivo functional assays demonstrated enhanced cytotoxic activity of T lymphocytes and natural killer cells following GS32 treatment, indicating that GS32 contributes to antitumor immunity alongside its direct cytotoxic effects. These findings suggest that GS32 acts through both tumor-intrinsic and immune-mediated mechanisms. Combination studies with immune checkpoint blockade revealed improved effects, suggesting that GS32 may enhance tumor responsiveness to immunotherapy, as demonstrated by tumor growth retardation and increased infiltration of the tumor microenvironment by immune cells. Collectively, these findings demonstrate that GS32 exerts robust antitumor activity through a dual mechanism involving direct tumor cell cytotoxicity and indirect modulation of the antitumor immune response. By inducing S-phase arrest and apoptosis, GS32 disrupts key proliferative and survival pathways in cancer cells, an effect supported by coordinated kinome reprogramming at the network level. Its efficacy in syngeneic tumor models, absence of systemic toxicity, and capacity to enhance immune cell infiltration and cytotoxic function further underscore its therapeutic potential. Moreover, the improved outcomes observed in combination with immune checkpoint blockade suggest that GS32 may sensitize tumors to immunotherapy. Collectively, these data indicate GS32 as a promising anticancer candidate that engages both tumor-intrinsic and immune-mediated mechanisms of action. In conclusion, this thesis presents a comprehensive preclinical evaluation of semi-synthetic analogs of olive-derived polyphenols and demonstrates that rational structural modifications thereof can substantially enhance their biological activity. GS50 and GS32 were identified as lead compounds with distinct yet complementary profiles, targeting inflammatory and oncogenic processes, respectively. GS50 functions as a modulator of acute inflammatory responses, whereas GS32 exhibits robust anticancer activity through combined cytotoxic and immunomodulatory mechanisms, data which support their further investigation as candidates for translational exploitation.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Angelis, Nikolaos
- Αγγέλης, Νικόλαος
Subjects
dc:subject × 22- Ελευρωπαΐνη
- Ημισυνθετικό ανάλογο
- Αντιφλεγμονώδης δραστικότητα
- Αντικαρκινική δραστικότητα
- Ανοσοτροποποίηση
- Oleuropein
- Semisynthetic analog
- Anti-inflammatory activity
- Anticancer activity
- Immunomodulation
- Βιολογία
- Φυσικές Επιστήμες
- Βιολογία, άλλοι τομείς
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Biological Sciences
- Natural Sciences
- Biology, miscellaneous
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61113